全文获取类型
收费全文 | 72377篇 |
免费 | 7206篇 |
国内免费 | 4182篇 |
专业分类
耳鼻咽喉 | 588篇 |
儿科学 | 982篇 |
妇产科学 | 1095篇 |
基础医学 | 8215篇 |
口腔科学 | 1226篇 |
临床医学 | 8591篇 |
内科学 | 11281篇 |
皮肤病学 | 827篇 |
神经病学 | 3356篇 |
特种医学 | 2908篇 |
外国民族医学 | 37篇 |
外科学 | 8553篇 |
综合类 | 11300篇 |
现状与发展 | 17篇 |
一般理论 | 17篇 |
预防医学 | 5079篇 |
眼科学 | 1741篇 |
药学 | 8024篇 |
59篇 | |
中国医学 | 4095篇 |
肿瘤学 | 5774篇 |
出版年
2024年 | 238篇 |
2023年 | 1077篇 |
2022年 | 2577篇 |
2021年 | 3487篇 |
2020年 | 2575篇 |
2019年 | 2324篇 |
2018年 | 2461篇 |
2017年 | 2212篇 |
2016年 | 2165篇 |
2015年 | 2998篇 |
2014年 | 3775篇 |
2013年 | 3829篇 |
2012年 | 5292篇 |
2011年 | 5636篇 |
2010年 | 3702篇 |
2009年 | 3046篇 |
2008年 | 3961篇 |
2007年 | 3966篇 |
2006年 | 3693篇 |
2005年 | 3468篇 |
2004年 | 2803篇 |
2003年 | 2731篇 |
2002年 | 2481篇 |
2001年 | 2068篇 |
2000年 | 1892篇 |
1999年 | 1654篇 |
1998年 | 903篇 |
1997年 | 911篇 |
1996年 | 712篇 |
1995年 | 590篇 |
1994年 | 518篇 |
1993年 | 355篇 |
1992年 | 555篇 |
1991年 | 467篇 |
1990年 | 426篇 |
1989年 | 374篇 |
1988年 | 293篇 |
1987年 | 290篇 |
1986年 | 219篇 |
1985年 | 174篇 |
1984年 | 125篇 |
1983年 | 90篇 |
1982年 | 61篇 |
1981年 | 79篇 |
1980年 | 41篇 |
1979年 | 75篇 |
1978年 | 37篇 |
1974年 | 39篇 |
1973年 | 34篇 |
1972年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
The antiparasitic drug, suramin, has antiproliferative effects in human carcinoma cells. It has been suggested that this occurs through blockade of growth factor-receptor interactions. Three types of evidence that suramin rapidly inhibits cellular respiration or disrupts cellular energy balance in intact cells of the human prostate carcinoma cell line, DU145, are presented. Beginning at approximately 10(-4) M, suramin rapidly causes dose-dependent inhibition of tetrazolium conversion by mitochondrial dehydrogenases in intact cells, demonstrating an inhibition of respiration. This effect is reversed by exchange with suramin-free media but not by pretreatment with serum, epidermal growth factor, insulin-like growth factor I, acidic and basic fibroblast growth factors, or calcium. Rhodamine 123 (10 micrograms/ml) uptake by mitochondria in intact DU145 cells is inhibited in the presence of 10(-3) M suramin. Treatment with 10(-4)-10(-3) M suramin causes the loss of rhodamine 123 from cells with mitochondria prestained with rhodamine 123, indicating that suramin is acting as an ionophore or respiratory poison. Also shown by electron microscopy are progressive toxic changes in mitochondria of DU145 cells within 1 h after treatment with 10(-4) M suramin. These data indicate that in intact DU145 cells 10(-4) M suramin rapidly disrupts cellular energy balance or respiration as seen by three studies of mitochondrial state. Disruption of energy balance or respiration represents a likely antiproliferative mechanism, as is thought to be a primary mechanism for the action of suramin in parasitic diseases. This proposed mechanism of action for suramin can explain the most prominent observed clinical toxicities of nephrotoxicity, adrenal toxicity, coagulopathy, and demyelinating neuropathy. 相似文献
62.
63.
64.
65.
John Jenn-Yenn Lu Chi-Chia Cheng Shieu-Ming Chou Chang-Bor Hor Yi-Chen Yang Hsiang-Ling Wang 《Vaccine》2009
The first universal hepatitis B vaccination program for newborns in the world was launched in Taiwan in July 1984. Most studies on the effectiveness of hepatitis B vaccination focused on the seroprevalence of HBs Ag among children under 14 years old. Only few studies focused on the seropositivity of anti-HBs among adolescents aged 15–18 years old. The present study aimed to evaluate the impact of the nationwide hepatitis B vaccination program on the immunity to HBV infection and the necessity of boost among adolescents. In this study including eight annual seroprevalence surveys from 2000 to 2007, 2342 college entrants (1589 15-year-olds in group I and 753 18-year-olds in group II) and 1851 university freshmen (18-year-olds in group III) participated. Subjects identified anti-HBs, HBs Ag and anti-HBc negative were given boost three doses of HBV vaccine. The HBs Ag seroprevalence was 11.6%, 3.5% and 1.0% for participants who were born before 1984, 1984–1986 and after 1986. The anti-HBs-seropositive rates were significantly higher in group II (83.1%) than in group I (53.0%) and group III (53.5%). All 572 participants who were seronegative for anti-HBs, HBs Ag and anti-HBc became anti-HBs-seropositive after catch-up vaccination. It is concluded that the anti-HBs-seropositive rate decreased to 50% in 15 years after vaccination, and boost vaccination was 100% effective. The necessity and age for boost among anti-HBs negative adolescents and the timing of the first immunization should be further evaluated. 相似文献
66.
Background The incidence rate of incisional hernias after open surgery has been reported to be higher than that of port site hernias
after laparoscopic surgery. No studies have compared the costs for the health care system in treating those two types of hernia.
Methods A systematic review was conducted to obtain the baseline data, and a decision analysis model was created to simulate the occurrence
and recurrence of incisional and port site hernias.
Results The overall risk of having incisional hernias was eight-times higher than that of having port site hernias (7.4% vs 0.9%).
A cost savings of £93 per patient can be generated for the health care system in the UK. Similar results were obtained for
Germany, Italy and France.
Conclusions The additional treatment costs for incisional hernia should be taken into account when the costs of a surgery performed by
open approach are compared with by laparoscopy. 相似文献
67.
有限内固定结合外固定支架治疗胫骨远端骨折 总被引:5,自引:2,他引:3
目的探讨有限内固定结合Hybrid外固定支架治疗胫骨远端骨折的疗效。方法从2003年1月~2005年7月,使用Hybird外固定支架治疗胫骨远端骨折21例,按AO分类:A1型4例;A2型5例;A3型4例;C1型2例;C2型3例;C3型3例,其中开放性骨折8例,手术采用有限切开,骨片钉固定,Hybrid外固定支架不跨踝关节固定。结果术后21例均获随访,平均随访时间12.3个月,骨折平均愈合时间7.6个月。功能评定采用Bone的踝关节活动度进行评价,优良率达76%。结论Hybrid外固定支架设计合理并能维持骨干的轴线,骨片钉能很好的固定骨折块,同时避免了软组织的并发症,可使踝关节早期活动,防止踝关节僵硬,因而是治疗胫骨远端骨折有效的方法之一。 相似文献
68.
69.
Yew Kuang Cheng Paul A Decker Megan M O'Byrne Catherine R Weiler 《Annals of allergy, asthma & immunology》2006,97(3):306-311
BACKGROUND: There are limited studies of large cohorts of patients with specific polysaccharide antibody deficiency (SPAD) syndrome. OBJECTIVE: To study the clinical and laboratory characteristics of patients with specific polysaccharide antibody deficiency syndrome. METHODS: We retrospectively studied 75 patients with total IgG levels of at least 500 mg/dL and fewer than 9 of 12 responses to vaccination with pneumococcal vaccine polyvalent. Exclusion criteria included an IgG level less than 500 mg/dL, established immunodeficiency syndrome, and secondary immunodeficiency. RESULTS: The most common clinical presentation was frequent infections (n = 69; 92%), including sinusitis (n = 53; 77%), pneumonia (n = 29; 42%), ear infections (n = 18; 26%), and bronchitis (n = 19; 28%). Other presentations were systemic infections (n = 5; 7%), autoimmune or rheumatic diseases (n = 6; 8%), and chronic diarrhea (n = 4; 5%). The median IgG2 level of patients with no response to pneumococcal vaccine polyvalent tended to be lower than that of patients with at least 1 response (150 vs 193 mg/dL, respectively; P = .06). There was no association between total IgG level (categorized as 500-600 or > or = 600 mg/dL) and frequency of infection (P = .43). Patients with fewer responses to pneumococcal vaccine polyvalent and a higher frequency of infections were more likely to receive intravenous immunoglobulin (IVIG) therapy (P = .01 and .003, respectively). Treatment with IVIG significantly reduced the number of infections (P < .001). CONCLUSION: Patients with no response to pneumococcal vaccine polyvalent tended to have lower IgG2 levels; those with fewer responses were more likely to receive IVIG therapy. 相似文献
70.